Xinhua News Agency, Beijing, February 4 (Reporters: Chen Cong, Liu Yizhan) At the press conference held on February 4 by the National Health Commission, Sun Yanrong, deputy head of China National Center for Biotechnology Development under the Ministry of Science and Technology, said, since the outbreak of the viral pneumonia, scientific research has been closely centered on clinical demands and the actual effect of prevention and control measures, and the current research and development of anti-virus drugs has been primarily aimed to increase the recovery rate and lower the death rate.
Sun added, the Ministry of Science and Technology is conducting a systematic, large-scale screening on drugs on sale and those in clinical trial and has found that, in addition to the antiviral drug Remdesivir, avloclor, Favipiravir and some Chinese traditional patent medicine also have antiviral activity. Their animal experiment and clinical experiment are under way successively.
科技部:正在开展抗病毒药物筛选工作
来源: 新华网
新华社北京2月4日电(记者陈聪、刘奕湛)科技部生物中心副主任孙燕荣4日说,新型冠状病毒感染的肺炎疫情发生以来,我们把科研攻关工作与临床需求、防控实践紧密结合,在药物研发方面,主要将提高治愈率、降低病死率作为应急科研攻关的重中之重。
孙燕荣在国家卫生健康委员会当天举行的新闻发布会上说,科技部正在已经上市的和正在开展临床试验的药物中进行系统化的、大规模的筛选,除抗病毒药物瑞德西韦外,发现了磷酸氯喹、法匹拉韦,以及中成药中一批具有抗病毒活性的上市药物。目前,科研团队正在递次推进动物实验和临床试验。
欢迎您使用本网站互动功能!本网站互动用户已实现与河北政务服务网统一登录,如上图所示,新用户请点击[注册]打开河北政务服务网完成注册。如果您已完成注册,请点击[登录],从河北政务服务网登录后可自动返回到本网站互动版块,然后您就可以写信提交了。